Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teva Pharmaceutical (TEVA) and GenMark (GNMK).
Teva Pharmaceutical (TEVA)
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Teva Pharmaceutical. The company’s shares closed last Monday at $11.15.
According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -1.7% and a 44.1% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Teva Pharmaceutical has an analyst consensus of Hold, with a price target consensus of $10.00.
See today’s analyst top recommended stocks >>
GenMark (GNMK)
Raymond James analyst Andrew Cooper maintained a Hold rating on GenMark today. The company’s shares closed last Monday at $23.98.
According to TipRanks.com, Cooper is a 4-star analyst with an average return of 15.6% and a 62.9% success rate. Cooper covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Idexx Laboratories, and NeoGenomics.
The word on The Street in general, suggests a Hold analyst consensus rating for GenMark with a $24.05 average price target, which is a 0.8% upside from current levels. In a report released today, Needham also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
